全文获取类型
收费全文 | 16038篇 |
免费 | 1024篇 |
国内免费 | 900篇 |
专业分类
耳鼻咽喉 | 29篇 |
儿科学 | 117篇 |
妇产科学 | 41篇 |
基础医学 | 1384篇 |
口腔科学 | 153篇 |
临床医学 | 749篇 |
内科学 | 1225篇 |
皮肤病学 | 156篇 |
神经病学 | 533篇 |
特种医学 | 457篇 |
外国民族医学 | 3篇 |
外科学 | 399篇 |
综合类 | 2992篇 |
现状与发展 | 1篇 |
预防医学 | 1484篇 |
眼科学 | 100篇 |
药学 | 6238篇 |
1篇 | |
中国医学 | 1596篇 |
肿瘤学 | 304篇 |
出版年
2023年 | 123篇 |
2022年 | 199篇 |
2021年 | 276篇 |
2020年 | 318篇 |
2019年 | 288篇 |
2018年 | 299篇 |
2017年 | 326篇 |
2016年 | 355篇 |
2015年 | 402篇 |
2014年 | 775篇 |
2013年 | 945篇 |
2012年 | 1029篇 |
2011年 | 1213篇 |
2010年 | 941篇 |
2009年 | 745篇 |
2008年 | 892篇 |
2007年 | 989篇 |
2006年 | 843篇 |
2005年 | 725篇 |
2004年 | 626篇 |
2003年 | 560篇 |
2002年 | 436篇 |
2001年 | 430篇 |
2000年 | 400篇 |
1999年 | 281篇 |
1998年 | 252篇 |
1997年 | 233篇 |
1996年 | 205篇 |
1995年 | 195篇 |
1994年 | 197篇 |
1993年 | 161篇 |
1992年 | 179篇 |
1991年 | 210篇 |
1990年 | 180篇 |
1989年 | 152篇 |
1988年 | 153篇 |
1987年 | 126篇 |
1986年 | 118篇 |
1985年 | 230篇 |
1984年 | 225篇 |
1983年 | 159篇 |
1982年 | 145篇 |
1981年 | 98篇 |
1980年 | 80篇 |
1979年 | 71篇 |
1978年 | 47篇 |
1977年 | 38篇 |
1976年 | 23篇 |
1975年 | 17篇 |
1974年 | 15篇 |
排序方式: 共有10000条查询结果,搜索用时 93 毫秒
31.
目的 通过GC-TOF-MS代谢组学探讨不同剂量的黄连解毒汤对SD大鼠粪便代谢组的影响,进而为黄连解毒汤的作用机制提供参考。方法 SD大鼠45只适应性喂养7天后,随机分为5组:黄连解毒汤高剂量组、中剂量组、低剂量组、抗生素组和空白组,每组9只。中药干预组不同剂量黄连解毒汤灌胃,1 mL/次,2次/天,连续给药21天;抗生素组,1 mL/次,2次/天;空白组生理盐水灌胃,1 mL/次,2次/天,连续给药21天;末次给药后,禁食禁水12 h,处死并收集大鼠粪便。采用气相色谱-飞行时间质谱(Gas Chromatography Tandem Time-of Flight Mass Spectrometry,GC-TOF-MS)检测各组大鼠粪便,运用多元分析OPLS以及单变量统计学方法筛选差异代谢物,通过MetaboAnalyst平台进行代谢通路分析。结果 对于粪便中的内源性代谢物小分子,高剂量组的黄连解毒汤影响的主要有:核糖、硫酸、棕榈酸、花生酸、茜素等;中剂量组的黄连解毒汤影响的主要有:乌头酸、胆固醇、乳酸、棕榈油酸、茜素等;低剂量组的黄连解毒汤影响的主要有:硫酸、棉子糖;氨苄西林钠影响的主要有:蛋氨酸1、麦角固醇、正亮氨酸1、棕榈酸、硫酸、乳酸等;不同剂量的黄连解毒汤和氨苄西林钠都能够影响到半乳糖代谢及硫代谢通路。结论 黄连解毒汤可改善糖尿病和心脑血管疾病相关的代谢物小分子,不同剂量的黄连解毒汤对粪便代谢的影响不同,其中中剂量的影响最为广泛。 相似文献
32.
《药学学报(英文版)》2020,10(10):1835-1845
Repurposing small molecule drugs and drug candidates is considered as a promising approach to revolutionise the treatment of snakebite envenoming. In this study, we investigated the inhibiting effects of the small molecules varespladib (nonspecific phospholipase A2 inhibitor), marimastat (broad spectrum matrix metalloprotease inhibitor) and dimercaprol (metal ion chelator) against coagulopathic toxins found in Crotalinae (pit vipers) snake venoms. Venoms from Bothrops asper, Bothrops jararaca, Calloselasma rhodostoma and Deinagkistrodon acutus were separated by liquid chromatography, followed by nanofractionation and mass spectrometry identification undertaken in parallel. Nanofractions of the venom toxins were then subjected to a high-throughput coagulation assay in the presence of different concentrations of the small molecules under study. Anticoagulant venom toxins were mostly identified as phospholipases A2, while procoagulant venom activities were mainly associated with snake venom metalloproteinases and snake venom serine proteases. Varespladib was found to effectively inhibit most anticoagulant venom effects, and also showed some inhibition against procoagulant toxins. Contrastingly, marimastat and dimercaprol were both effective inhibitors of procoagulant venom activities but showed little inhibitory capability against anticoagulant toxins. The information obtained from this study aids our understanding of the mechanisms of action of toxin inhibitor drug candidates, and highlights their potential as future snakebite treatments. 相似文献
33.
Hericium novae-zealandiae is a native mushroom consumed by indigenous Māori people in New Zealand. The lipophilic mycochemicals of the mushroom were isolated using a normal column chromatography combined with a preparative HPLC. Structural characterisation based on spectroscopic methods, namely UV, MS, NMR and single crystal XRD have identified three lipophilic compounds as hericene B (a compound unique to Hericium), ergosterol and ergosterol peroxide. Following this, an HPLC-DAD method was developed and validated to quantify the hericene B and ergosterol. The method showed excellent selectivity, linearity, precision, accuracy and robustness. The content of hericene B was determined as 28.53 mg/g by dry weight of H. novae-zealandiae (approximately 3%). This discovery indicates the potential utilisation of H. novae-zealandiae as a natural source of hericene B. Current research revealed for the first time, the lipophilic constituents of H. novae-zealandiae and the method development for quantification of hericene B in the above species. 相似文献
34.
We have established a novel hydrophilic chromatography (HILIC)-high performance liquid chromatography (HPLC) method to assess sialic acid content in food products. Single-factor and response surface methodologies (RSM) were used to systematically optimize the hydrolysis conditions of the food samples to extract the maximum amount of sialic acid. Chromatographic conditions were also adjusted. In foods containing sialic acid, we observed a strong linear relationship between sialic acid and peak area, ranging from 5 to 100 μg/mL (R2 = 0.9998). The lowest detectable sialic acid concentration (RSN = 3) was 0.2 μg mL−1, and the method detection limit was 0.02mg kg−1. Sample recovery ranged from 95.85% to 99.78%, with an RSD of 1.46% (n = 6). Thus, the described method can be applied to the study of sialic acid content in foods. 相似文献
35.
36.
《Yao wu shi pin fen xi = Journal of food and drug analysis.》2019,27(2):510-517
Vitamin D has been considered to regulate calcium and phosphorus homeostasis and to preserve skeletal integrity. Serum 25-hydroxyvitamin D (25(OH)D) is the best indicator of vitamin D levels. The association of serum 25(OH)D deficiency with increased risk of type 1 diabetes (T1DM) and type 2 diabetes (T2DM) is controversial. We investigated serum 25(OH)D2 and 25(OH)D3 levels in diabetes patients by using liquid chromatography tandem mass spectrometry (LC-MS/MS). Serum 25(OH)D2 and 25(OH)D3 levels were measured with liquid chromatography tandem mass spectrometry in electrospray ionization positive mode. Chromatograms were separated using an ACE5 C18 column on a gradient of methanol. The total 25(OH)D levels were calculated as the sum of 25(OH)D3 and 25(OH)D2 levels. A total of 56 patients with T1DM and 41 patients with T2DM were enrolled in this study. There were 42 and 28 non-diabetic, age-matched volunteers who participated as the T1DM controls and the T2DM controls, respectively. The total 25(OH)D levels were lowest in the 21–40 age group. The levels of both 25(OH)D3 and the total 25(OH)D were significantly higher in the T1DM and T2DM groups than in the controls (p < 0.01 in T1DM and p < 0.05 in T2DM group, respectively). The 25(OH)D2 levels were only significantly higher in T1DM patients than in the controls. The percentages of vitamin D deficiency (total 25(OH)D less than 20 ng/mL) in the T1DM, T2DM, the T1DM controls and the T2DM controls were 7.1%, 0%, 14.3% and 3.6%, respectively. The percentages of vitamin D insufficiency (total 25(OH)D less than 30 ng/mL) in the T1DM, T2DM, the T1DM controls and the T2DM controls were 26.8%, 7.3%, 54.8% and 17.9%, respectively. The percentages of vitamin D deficiency and insufficiency were significantly lower in the T1DM patients than in the T1DM controls (p < 0.01). In the present study, both type 1 and type 2 diabetes patients had higher serum 25(OH)D levels and lower percentages of vitamin D deficiency/insufficiency. 相似文献
37.
《Journal of pharmaceutical sciences》2019,108(10):3312-3318
Daclatasvir hydrochloride (DCV) is the active pharmaceutical ingredient of Daklinza, a marketed product for the treatment of hepatitis C viral infection. The intrinsic stability of daclatasvir was evaluated via a forced degradation study. DCV was found to be stable in the solid state. In solution, its carbamate moiety is susceptible to basic hydrolysis, whereas its imidazole is liable to base-mediated autoxidation to form degradants 1 and 3, 7-8, respectively. The imidazole moiety can also be oxidized to form degradants 6-7 in the presence of hydrogen peroxide or azobisisobutyronitrile. The chloro-adduct degradant 9 was also observed in hydrogen peroxide solution. Furthermore, the imidazole moiety is sensitive to photodegradation in solution. Degradants 2-8 were observed in a solution of DCV exposed to high intensity light/UV light; the formation of degradants 2 and 5-8 was postulated through 4 degradation pathways. The degradants 3 and 4 were deemed to be secondary degradants of 7 and 5, respectively. 相似文献
38.
《Drug metabolism and pharmacokinetics》2019,34(1):87-94
The purpose of this study was to elucidate the involvement of Mate1 in the tubular secretion of trimethoprim and saturation of Mate1-mediated efflux to address the mechanisms underlying the pharmacokinetic drug interactions with trimethoprim. Trimethoprim is a more potent inhibitor of MATE2-K than MATE1 with Ki values (μM) of 0.030–0.28 and 2.4–5.9, respectively. Trimethoprim is a substrate of human MATE1 and MATE2-K with Km values of 2.3 ± 0.9 and 0.018 ± 0.004 μM, and mouse Mate1, but not human OCT2, mouse Oct1 and Oct2. Pyrimethamine significantly reduced the renal clearance (CLR) of trimethoprim (mL/min/kg) from 40.0 ± 5.1 to 20.1 ± 3.7 (p < 0.05). Trimethoprim was given to mice at three infusion rates (150, 500, and 1500 nmol/min/kg). Together with an increase in the plasma concentrations of trimethoprim, the CLR (mL/min/kg) of trimethoprim decreased to 25.9 ± 3.2, 13.5 ± 5.7, and 8.92 ± 1.50 at the respective rates. Trimethoprim decreased the CLR of rhodamine 123 in an infusion rate-dependent manner: 11.5 ± 1.3 (control), 5.17 ± 1.55, 1.31 ± 0.50, and 0.532 ± 0.180. These results suggest that Mate1 mediates the tubular secretion of trimethoprim, and at therapeutic doses, MATEs-mediated efflux can be saturated, and thereby, cause drug interactions with other MATE substrates. 相似文献
39.
40.
《药学学报(英文版)》2020,10(8):1453-1475
Angiokinases, such as vascular endothelial-, fibroblast- and platelet-derived growth factor receptors (VEGFRs, FGFRs and PDGFRs) play crucial roles in tumor angiogenesis. Anti-angiogenesis therapy using multi-angiokinase inhibitor has achieved great success in recent years. In this study, we presented the design, synthesis, target identification, molecular mechanism, pharmacodynamics (PD) and pharmacokinetics (PK) research of a novel triple-angiokinase inhibitor WXFL-152. WXFL-152, identified from a series of 4-oxyquinoline derivatives based on a structure–activity relationship study, inhibited the proliferation of vascular endothelial cells (ECs) and pericytes by blocking the angiokinase signals VEGF/VEGFR2, FGF/FGFRs and PDGF/PDGFRβ simultaneously in vitro. Significant anticancer effects of WXFL-152 were confirmed in multiple preclinical tumor xenograft models, including a patient-derived tumor xenograft (PDX) model. Pharmacokinetic studies of WXFL-152 demonstrated high favourable bioavailability with single-dose and continuous multi-dose by oral administration in rats and beagles. In conclusion, WXFL-152, which is currently in phase Ib clinical trials, is a novel and effective triple-angiokinase inhibitor with clear PD and PK in tumor therapy. 相似文献